Allogene Therapeutics, Inc. Income (Loss) from Equity Method Investments
Allogene Therapeutics, Inc. (ALLO) reported Income (Loss) from Equity Method Investments of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-03-12
- Allogene Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2025-12-31 was $0.00.
- Allogene Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2025-09-30 was $0.00.
- Allogene Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Allogene Therapeutics, Inc. income (loss) from equity method investments for the quarter ending 2025-03-31 was $0.00.
- Allogene Therapeutics, Inc. income (loss) from equity method investments for fiscal 2025 was $0.00.
- Allogene Therapeutics, Inc. income (loss) from equity method investments for fiscal 2024 was -$1.69M.
- Allogene Therapeutics, Inc. income (loss) from equity method investments for fiscal 2023 was -$10.67M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | -$1.13M derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | -$1.13M derived: sum of 3 quarters · filed 2026-03-12 | -$759.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$1.13M derived: sum of 2 quarters · filed 2026-03-12 | -$759.00K derived: sum of 3 quarters · filed 2026-03-12 | -$1.69M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$759.00K derived: sum of 2 quarters · filed 2025-11-06 | -$1.69M 10-Q · filed 2025-11-06 | -$4.49M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $375.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$554.00K 10-Q · filed 2025-08-13 | -$3.36M derived: sum of 3 quarters · filed 2025-08-13 | -$5.86M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$929.00K 10-Q · filed 2025-05-13 | -$3.73M derived: sum of 2 quarters · filed 2025-05-13 | -$6.23M derived: sum of 3 quarters · filed 2025-05-13 | -$8.67M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$5.30M derived: sum of 2 quarters · filed 2025-03-13 | -$7.74M derived: sum of 3 quarters · filed 2025-03-13 | -$10.67M 10-K · filed 2025-03-13 |
| 2023-09-30 | -$2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$4.93M derived: sum of 2 quarters · filed 2024-11-07 | -$7.87M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$2.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$5.37M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$2.94M 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |